Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 394,886,784
  • Shares Outstanding, K 1,767,385
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,034 M
  • EBITDA $ 17,420 M
  • 60-Month Beta 0.35
  • Price/Sales 6.33
  • Price/Cash Flow 14.67
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 25.72% (-2.15%)
  • Historical Volatility 28.63%
  • IV Percentile 47%
  • IV Rank 23.92%
  • IV High 51.27% on 04/08/25
  • IV Low 17.68% on 02/19/25
  • Expected Move (DTE 4) 5.48 (2.45%)
  • Put/Call Vol Ratio 0.52
  • Today's Volume 20,328
  • Volume Avg (30-Day) 51,248
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 229,560
  • Open Int (30-Day) 239,253
  • Expected Range 217.95 to 228.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.01
  • Number of Estimates 7
  • High Estimate 3.17
  • Low Estimate 2.95
  • Prior Year 2.46
  • Growth Rate Est. (year over year) +22.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
204.27 +9.38%
on 02/04/26
237.04 -5.74%
on 01/07/26
-0.50 (-0.22%)
since 01/06/26
3-Month
204.27 +9.38%
on 02/04/26
239.29 -6.63%
on 11/13/25
+4.39 (+2.00%)
since 11/06/25
52-Week
164.39 +35.91%
on 04/09/25
244.81 -8.73%
on 10/01/25
+30.46 (+15.78%)
since 02/06/25

Most Recent Stories

More News
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

AbbVie is on track to grow, drive cash flow, and pay a healthy dividend for the long term: institutions and analysts are accumulating this stock.

ABT : 110.83 (+1.60%)
ABBV : 223.43 (+2.01%)
ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds

ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds

ABBV : 223.43 (+2.01%)
AbbVie: Q4 Earnings Snapshot

AbbVie: Q4 Earnings Snapshot

ABBV : 223.43 (+2.01%)
AbbVie’s (NYSE:ABBV) Q4 CY2025: Beats On Revenue

AbbVie’s (NYSE:ABBV) Q4 CY2025: Beats On Revenue

ABBV : 223.43 (+2.01%)
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

NORTH CHICAGO, Ill. , Feb. 4, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2025.

ABBV : 223.43 (+2.01%)
Stock Index Futures Steady After Tech-Led Selloff, U.S. ADP Jobs Report and Alphabet Earnings in Focus

March S&P 500 E-Mini futures (ESH26) are up +0.11%, and March Nasdaq 100 E-Mini futures (NQH26) are up +0.01% this morning, steadying after yesterday’s tech-led selloff, while investors await the U.S....

ACA.FP : 18.020 (+0.87%)
GOOGL : 322.86 (-2.53%)
BSX : 76.27 (-1.76%)
SMCI : 34.38 (+11.44%)
MU : 394.69 (+3.08%)
TRI : 88.07 (-0.27%)
IT : 156.33 (+2.83%)
ABBV : 223.43 (+2.01%)
ESH26 : 6,959.50 (+0.10%)
NOVOB.C.DX : 319.650 (+8.36%)
QCOM : 137.34 (+0.76%)
EPAM : 186.68 (+5.19%)
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

IRVINE, Calif. , Feb. 3, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of the Faces of Natrelle ® Testimonial Program...

ABBV : 223.43 (+2.01%)
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

NORTH CHICAGO, Ill. , Feb. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and...

ABBV : 223.43 (+2.01%)
AbbVie (ABBV) Q4 Earnings: What To Expect

AbbVie (ABBV) Q4 Earnings: What To Expect

ABBV : 223.43 (+2.01%)
Stocks Set to Open Lower as Risk Sentiment Weakens, U.S. Jobs Data and Earnings in Focus

March S&P 500 E-Mini futures (ESH26) are down -0.57%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.92% this morning, pointing to a lower open on Wall Street as investors continue to sell risky...

MSTR : 134.93 (+26.11%)
GOOGL : 322.86 (-2.53%)
HL : 22.77 (+6.85%)
CDE : 21.44 (+12.19%)
PFE : 27.22 (+2.76%)
COIN : 165.12 (+13.00%)
QCOM : 137.34 (+0.76%)
NQH26 : 25,183.00 (+0.08%)
AMD : 208.44 (+8.28%)
LLY : 1,058.18 (+3.66%)
UBER : 74.77 (-0.59%)
PLTR : 135.90 (+4.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 233.99
2nd Resistance Point 229.90
1st Resistance Point 226.67
Last Price 223.43
1st Support Level 219.35
2nd Support Level 215.26
3rd Support Level 212.03

See More

52-Week High 244.81
Last Price 223.43
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar